...
首页> 外文期刊>The Lancet >Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.
【24h】

Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.

机译:口服避孕药对人乳头瘤病毒感染妇女宫颈癌风险的影响:IARC多中心病例对照研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Use of oral contraceptives could increase risk of cervical cancer; however the effect of human papillomavirus (HPV), the main cause of cervical cancer, is not usually taken into account. We aimed to assess how use of oral contraceptives affected risk of cervical cancer in women who tested positive for HPV DNA. METHODS: We pooled data from eight case-control studies of patients with histologically confirmed invasive cervical carcinoma (ICC) and from two studies of patients with carcinoma in situ (ISC). Information about use of oral contraceptives was obtained from personal interviews. Effects were estimated as odds ratios, with logistic-regression models adjusted for possible confounders. FINDINGS: 1465 of 1561 (94%) patients with ICC, 211 of 292 (72%) with ISC, and 255 of 1916 (13%) controls were positive for HPV DNA. Compared with never-users, patients who had used oral contraceptives for fewer than 5 years did not have increased risk of cervical cancer (odds ratio 0.73; 95% CI 0.52-1.03). The odds ratio for use of oral contraceptives was 2.82 (95% CI 1.46-5.42) for 5-9 years, and 4.03 (2.09-8.02) for use for 10 years or longer, and these risks did not vary by time since first or last use. INTERPRETATION: Long-term use of oral contraceptives could be a cofactor that increases risk of cervical carcinoma by up to four-fold in women who are positive for cervical HPV DNA. In the absence of worldwide information about HPV status, extra effort should be made to include long-term users of oral contraceptives in cervical screening programmes.
机译:背景:使用口服避孕药可能增加患子宫颈癌的风险。但是,通常不会考虑宫颈癌的主要病因-人乳头瘤病毒(HPV)的影响。我们旨在评估使用口服避孕药如何影响HPV DNA检测呈阳性的女性患子宫颈癌的风险。方法:我们收集了八份组织学确诊的浸润性宫颈癌(ICC)患者的病例对照研究和两项原位癌(ISC)患者的研究数据。有关口服避孕药使用的信息是通过个人访谈获得的。估计效果为优势比,并针对可能的混杂因素调整了逻辑回归模型。结果:在1561名ICC患者中有1465名(94%)ISC患者,在292名ISC患者中有211名(72%)和1916年255名对照(13%)的HPV DNA阳性。与从未使用过避孕药的患者相比,使用口服避孕药少于5年的患者患宫颈癌的风险没有增加(优势比为0.73; 95%CI为0.52-1.03)。口服避孕药使用5-9年的几率是2.82(95%CI 1.46-5.42),使用10年或更长时间是4.03(2.09-8.02),并且这些风险自第一次或首次使用以来随时间而变化最后使用。解释:长期使用口服避孕药可能是使宫颈HPV DNA阳性的女性患宫颈癌的风险增加四倍的辅助因素。在缺乏有关HPV状况的全球信息的情况下,应做出额外的努力,将长期使用口服避孕药的人纳入宫颈筛查计划。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号